ReviewMolecular and biochemical parasitology2021
The role of different components of the immune system against Plasmodium falciparum malaria: Possible contribution towards malaria vaccine development.
Review in Molecular and biochemical parasitology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- Modelling the effect of long-lasting insecticidal nets on malaria transmission dynamics in Kebbi State, Nigeria.Infectious Disease Modelling · 2026Article
- Interferon-γ and Interleukin-10 Profiles Correlate with Disease Severity in Sudanese Children withJournal of clinical medicine · 2026Article
- Cellular Immune Response and T Cell Epitope Mapping ofVaccines · 2026Article
- Simultaneous serological assessment of vector and pathogen exposure to support intervention monitoring and understand host-vector interactions.Malaria journal · 2026Article
- Sex in Immune Cells and Parasitic Diseases - A Complex Relationship.Immunological reviews · 2026Review
- Hepatorenal protective role of encapsulatedJournal of advanced veterinary and animal research · 2026Article
- Hemozoin-induced immunomodulation and prostate carcinogenesis: mechanisms and implications.Frontiers in oncology · 2026Review
- Heme oxygenase-1 and malaria pathogenesis.Frontiers in immunology · 2026Review
- The efficacy of selected Ghanaian herbal antimalarials against laboratory strains and clinical isolates of Plasmodium falciparum.Scientific reports · 2025Article
- Generalist Malaria Parasites and Host Imprinting: Unveiling Transcriptional Memory.Molecular biology and evolution · 2025Article
- Computational analysis of luteolin, apigenin and their derivatives from Allophylus africanus as potential inhibitors of plasmepsin II a malaria target.BMC chemistry · 2025Article
- Phenotype and function of IL-10-producing NK cells in individuals with malaria experience.JCI insight · 2025Article
- New therapeutic strategies for malaria.Biophysical reviews · 2025Review
- A roadmap for understanding sulfadoxine-pyrimethamine in malaria chemoprevention.Parasitology · 2025Review
- Article
- Computational Development of Transmission-Blocking Vaccine Candidates Based on Fused Antigens of Pre- and Post-fertilization Gametocytes AgainstBioinformatics and biology insights · 2025Article
- Current Developments in Malaria Vaccination: A Concise Review on Implementation, Challenges, and Future Directions.Clinical pharmacology : advances and applications · 2025Review
- Plasmodium Falciparum and mosquito vector IgG patterns across suspected malaria cases in Ghana.BMC infectious diseases · 2024Article
- IdentifyingResearch square · 2024Article
- Plasmodium falciparum alters the trophoblastic barrier and stroma villi organization of human placental villi explants.Malaria journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmodium falciparum malaria still remains a major global public health challenge with over 220 million new cases and well over 400,000 deaths annually. Most of the deaths occur in sub-Saharan Africa which bears 90 % of the malaria cases. Such high P. falciparum malaria-related morbidity and mortality rates pose a huge burden on the health and economic wellbeing of the countries affected. Lately, substantial gains have been made in reducing malaria morbidity and mortality through intense malaria control initiatives such as use of effective antimalarials, intensive distribution and use of insecticide-treated nets (ITNs), and implementation of massive indoor residual spraying (IRS) campaigns. However, these gains are being threatened by widespread resistance of the parasite to antimalarials, and the vector to insecticides. Over the years the use of vaccines has proven to be the most reliable, cost-effective and efficient method for controlling the burden and spread of many infectious diseases, especially in resource poor settings with limited public health infrastructure. Nonetheless, this had not been the case with malaria until the most promising malaria vaccine candidate, RTS,S/AS01, was approved for pilot implementation programme in three African countries in 2015. This was regarded as the most important breakthrough in the fight against malaria. However, RTS,S/AS01 has been found to have some limitations, the main ones being low efficacy in certain age groups, poor immunogenicity and need for almost three boosters to attain a reasonable efficacy. Thus, the search for a more robust and effective malaria vaccine still continues and a better understanding of naturally acquired immune responses to the various stages, including the transmissible stages of the parasite, could be crucial in rational vaccine design. This review therefore compiles what is currently known about the basic biology of P. falciparum and the natural malaria immune response against malaria and progress made towards vaccine development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.